The World Health Organization (WHO) Global TB Program has initiated a process to conduct systematic reviews for the collection and assessment of available evidence on the prevalence of viral hepatitis B and C among patients with TB and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and whether the concurrent treatment of drug-resistant TB and hepatitis C is safe and increases the likelihood of treatment success and reduces unfavourable treatment outcomes.
The WHO Global TB Program is seeking support from an independent consultants or group/s of experts with relevant expertise and experience to undertake systematic reviews to synthesise the evidence on the above-mentioned topic.
The deadline for submission of expressions of interest is 30 April 2021.
For further details, click here.